Literature DB >> 24900140

Clinical significance of diffuse intrathoracic uptake on post-therapy I-131 scans in thyroid cancer patients.

Hyun Su Choi1, Sung Hoon Kim1, Sonya Youngju Park1, Hye Lim Park1, Ye Young Seo1, Woo Hee Choi2.   

Abstract

PURPOSE: The purpose of this study was to identify the frequency and possible cause of diffuse intrathoracic uptake on post-therapy I-131 scans in thyroid cancer patients.
METHODS: We retrospectively reviewed 781 post-therapy scans of 755 thyroid cancer patients who underwent total thyroidectomy and radioactive iodine therapy between January and December 2010. Diffuse intrathoracic uptake on post-therapy scans was examined, and clinical patient characteristics including sex, age, regimen for thyroid-stimulating hormone (TSH) stimulation (thyroid hormone withdrawal or recombinant human TSH injection), TSH, thyroglobulin (Tg) and anti-thyroglobulin antibody (anti-Tg Ab) levels, therapeutic dose of radioactive iodine therapy and prior history of radioactive iodine therapy were recorded.Scan findings were correlated with chest CT, chest radiographs, laboratory tests and/or clinical status. Diffuse intrathoracic uptake without evidence of pathologic condition was categorized as indeterminate. The association between clinical characteristics and intrathoracic uptake were analyzed for negative intrathoracic uptake and indeterminate uptake groups.
RESULTS: Diffuse intrathoracic uptake on post-therapy scans was demonstrated in 39 out of 755 (5.2 %) patients, among which 3 were confirmed as lung metastasis. The 14 patients that showed high Tg or anti-Tg Ab levels were considered to be at risk of having undetected micrometastasis on other imaging modalities. The remaining 22 were indeterminate (2.9 %).Upon comparison of negative intrathoracic uptake and indeterminate uptake groups, TSH stimulation by thyroid hormone withdrawal was shown to be significantly correlated with diffuse intrathoracic uptake (p < 0.05).
CONCLUSION: The frequency of diffuse intrathoracic uptake on post-therapy scans was 5.2 % and could be seen in thyroid cancer patients with underlying lung metastasis as well as those without definite pathologic condition. In the latter, there was a higher frequency for diffusely increased intrathoracic uptake in those who underwent thyroid hormone withdrawal rather than recombinant human TSH injection.

Entities:  

Keywords:  Post-therapy scan; Radioactive iodine therapy; Thyroid cancer

Year:  2013        PMID: 24900140      PMCID: PMC4035155          DOI: 10.1007/s13139-013-0234-4

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  30 in total

1.  False positive 131I whole body scans in thyroid cancer.

Authors:  G Mitchell; B E Pratt; L Vini; V R McCready; C L Harmer
Journal:  Br J Radiol       Date:  2000-06       Impact factor: 3.039

2.  Unusual case of well-differentiated papillary thyroid carcinoma lacking thyroglobulin expression while still concentrating radioiodine.

Authors:  B Singh; R Bollmann; H Ahmadzadehfar; H J Biersack; S Ezziddin
Journal:  Br J Radiol       Date:  2006-09       Impact factor: 3.039

3.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

4.  Thoracic 131I uptake after previous pneumonectomy in patients treated for differentiated thyroid cancer.

Authors:  Camila Nascimento; Boumédiène Bridji; Catherine Dejax; Martin Schlumberger; Sophie Leboulleux
Journal:  Clin Nucl Med       Date:  2012-06       Impact factor: 7.794

5.  Radioiodine uptake in inactive pulmonary tuberculosis.

Authors:  S M Bakheet; M M Hammami; J Powe; M Bazarbashi; H Al Suhaibani
Journal:  Eur J Nucl Med       Date:  1999-06

Review 6.  rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.

Authors:  Markus Luster; Francesco Lippi; Barbara Jarzab; Petros Perros; Michael Lassmann; Christoph Reiners; Furio Pacini
Journal:  Endocr Relat Cancer       Date:  2005-03       Impact factor: 5.678

7.  Diffuse 131I lung uptake in bronchiectasis: a potential pitfall in the follow-up of differentiated thyroid carcinoma.

Authors:  Vincenzo Triggiani; Marco Moschetta; Vito Angelo Giagulli; Brunella Licchelli; Edoardo Guastamacchia
Journal:  Thyroid       Date:  2012-10-15       Impact factor: 6.568

8.  Iodine-131 treatment and high-resolution CT: results in patients with lung metastases from differentiated thyroid carcinoma.

Authors:  Seyfettin Ilgan; A Ozgur Karacalioglu; Yuksel Pabuscu; G Kaan Atac; Nuri Arslan; Emel Ozturk; Bengul Gunalp; M Ali Ozguven
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02-05       Impact factor: 9.236

9.  A case of subclinical hypothyroidism developing marked pleural effusions and peripheral edema with elevated vascular endothelial growth factor.

Authors:  Yuji Hataya; Takashi Akamizu; Naotetsu Kanamoto; Kenji Moriyama; Akira Shimatsu; Kazuwa Nakao
Journal:  Endocr J       Date:  2007-07-13       Impact factor: 2.349

10.  The false-positive radioiodine I-131 uptake in the foreign body granuloma located in gluteal adipose tissue.

Authors:  Salih Sinan Gültekin; Alper Dilli; Ata Türker Arıkök; Hasan Bostancı; Ahmet Oğuz Hasdemir
Journal:  Radiol Oncol       Date:  2011-06-24       Impact factor: 2.991

View more
  2 in total

1.  Variants and pitfalls on radioiodine scans in pediatric patients with differentiated thyroid carcinoma.

Authors:  Mohamed Mostafa; Reza Vali; Jeffrey Chan; Yusuaf Omarkhail; Amer Shammas
Journal:  Pediatr Radiol       Date:  2016-08-03

2.  Predictive factors for the outcomes of Graves' disease patients with radioactive iodine (131I) treatment.

Authors:  Yu-Zhuo Xing; Kun Zhang; Gang Jin
Journal:  Biosci Rep       Date:  2020-01-31       Impact factor: 3.840

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.